Switzerland’s Vifor Pharma has forged an $80 million deal with Uniondale, N.Y.-based Angion for the international licensing rights to its investigational kidney drug ANG-3777.

Designed to activate the body's natural organ-repair process, ANG-3777 is meant to improve kidney function following organ transplant as well as in kidney injury associated with complications from heart surgery.

Under the licensing deal, Vifor Pharma will gain worldwide rights except in China, Taiwan, Hong Kong and Macau.

Angion will receive up to $80 million and an additional $260 million in milestone payments for U.S. and EU regulatory approvals.